The Parkinson’s Disease and Movement Disorder Center at Henry Ford Health System was the first in the United States to offer a new FDA-approved device to help treat the symptoms of Parkinson’s disease. Neurosurgeon Jason Schwalb, M.D. surgically implanted the Vercise Genus™ Deep Brain Stimulation (DBS) System, which stimulates a targeted region of the brain through implanted leads that are placed in the brain.
Parkinson’s is a neurological disorder that progressively attacks motor functions, leading to lasting damage in movement and coordination. Researchers studying the primary causes of the disease have focused on mutations of the protein known as leucine-rich repeat kinase 2, or LRRK2.
DALLAS – June 11, 2020 – Dopamine, a chemical that sends messages between different parts of the brain and body, plays a key role in a variety of diseases and behaviors by interacting with receptors on cells. But despite their importance in physiology and pathology, the structure of these receptors embedded in a phospholipid membrane – their natural environment on the cell surface – was unknown. A new study led by UT Southwestern researchers reveals the structure of the active form of one type of dopamine receptor, known as D2, embedded in a phospholipid membrane.
Researchers from the University of Kentucky’s College of Medicine are leading a clinical study that could provide a promising new method for early detection of Parkinson’s disease.